CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
We had previously demonstrated the role of CD103 integrin on lung tumor-infiltrating lymphocyte (TIL) clones in promoting specific TCR-mediated epithelial tumor cell cytotoxicity. However, the contribution of CD103 on intratumoral T cell distribution and functions and the prognosis significance of TIL subpopulations in non–small cell lung carcinoma (NSCLC) have thus far not been systematically addressed. In this study, we show that an enhanced CD103+ TIL subset correlates with improved early stage NSCLC patient survival and increased intraepithelial lymphocyte infiltration. Moreover, our results indicate that CD8+CD103+ TIL, freshly isolated from NSCLC specimens, display transcriptomic and phenotypic signatures characteristic of tissue-resident memory T cells and frequently express PD-1 and Tim-3 checkpoint receptors. This TIL subset also displays increased activation-induced cell death and mediates specific cytolytic activity toward autologous tumor cells upon blockade of the PD-1–PD-L1 interaction. These findings emphasize the role of CD8+CD103+ tissue-resident memory T cells in promoting intratumoral CTL responses and support the rationale for using anti–PD-1 blocking Ab to reverse tumor-induced T cell exhaustion in NSCLC patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further research revealed that the presence of CD103+CD8+ TILs is a positive prognostic marker in several cancers [269-272].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [270]
In the citing paper
“Previous studies demonstrated that enhanced CD8+CD103+ TRM TILs correlate with improved survival in patients with early stage NSCLC18 and with other types of cancer19.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [18]
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“types of advanced solid tumors, including NSCLC (43, 44).”
BackgroundTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · cited 1×
“both molecules has been reported to transmit a death signal to T cells (40, 41).”
BackgroundUpregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., et al. (2006) · Nature Medicine · doi:10.1038/nm1482 · Cited by 1,565
The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin
Mackay, L. K., Rahimpour, A., Ma, J. Z., Collins, N., Stock, A. T., Hafon, M.-L., Vega-Ramos, J., Lauzurica, P., Mueller, S. N., Stefanovic, T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2744 · Cited by 1,331 · cited 5×
“Indeed, downregulation of SIP1 was observed in CD103CD8 TRM T cells (18) and appeared to be required for their retention in peripheral tissues (28).”
BackgroundInfluentialFourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307 · cited 1×
“Among these inhibitory receptors, CTLA-4, PD-1, and Tim3 appeared to be associated with T cell exhaustion in chronic viral infections (35–38) and tumor progression (39).”
BackgroundPD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111 · cited 1×
“In the latter and present studies, CD103 T cells expressed high levels of PD-1, which has been defined as a biomarker of tumor-specific T cells (33).”
BackgroundSkin infection generates non-migratory memory CD8+ TRM cells providing global skin immunity
Jiang, X., Clark, R. A., Liu, L., Wagers, A. J., Fuhlbrigge, R. C., & Kupper, T. S. (2012) · Nature · doi:10.1038/nature10851 · Cited by 891 · cited 1×
“TRM T cells are highly activated T lymphocytes that reside within a variety of peripheral tissues, including intestine (17, 20), brain (21), skin (22, 23), and lung”
Background
Cited by
Items 101–200 of 661
Hofman, P. M., Badoual, C., Henderson, F., Berland, L., Hamila, M., Long-Mira, É., Lassalle, S., Roussel, H., Hofman, V., Tartour, É., et al. (2019) · Cancers · doi:10.3390/cancers11030283 · Cited by 127
“These data were then confirmed by various clinical studies [63,64].”
Zhu, W., Germain, C., Liu, Z., Sebastian, Y., Devi, P., Knockaert, S., Brohawn, P., Lehmann, K., Damotte, D., Validire, P., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1051922 · Cited by 113
Self-citationResident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients
Egelston, C. A., Avalos, C., Tu, T. Y., Rosario, A., Wang, R., Solomon, S. T., Srinivasan, G., Nelson, M. S., Huang, Y., Lim, M. H., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.130000 · Cited by 159
“The presence of tumor infiltrating CD103 CD8 TRMs have been implicated to be associated with improved survival prognosis in head and neck cancer, non-small cell lung cancer, ovarian cancer, and skin cancer patients (20-23).”
BackgroundTantalo, D. G. M., Oliver, A. J., von Scheidt, B., Harrison, A. J., Mueller, S. N., Kershaw, M. H., & Slaney, C. Y. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002555 · Cited by 122
Local heroes or villains: tissue-resident memory T cells in human health and disease
Sasson, S. C., Gordon, C. L., Christo, S. N., Klenerman, P., & Mackay, L. K. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0359-1 · Cited by 111
“In vitro, CD103 TRM-like TILs were more efficient at lysing NSCLC cells than their CD103 counterparts, possibly due to these cells being able to form more stable synapses with target cells and to direct cytotoxic granules in a polarized fashion.(145,158) Similarly, CD39CD103CD8 TRM-like TILs had the highest tumor reac…”
BackgroundBoutet, M., Gauthier, L., Leclerc, M., Gros, G., de Montpreville, V., Théret, N., Donnadieu, E., & Mami-Chouaib, F. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1545 · Cited by 104
“Moreover, an enhanced CD103 TIL subset correlates with improved patient survival in ovarian (15) and lung (16) carcinomas and increased intraepithelial lymphocyte infiltration, suggesting that CD103 promotes recruitment of TIL within epithelial tumor islets.”
BackgroundSelf-citationTissue Resident CD8 Memory T Cell Responses in Cancer and Autoimmunity
Molodtsov, A., & Turk, M. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02810 · Cited by 106
“Detailed flow cytometric and qPCR analyses of CD103+CD8+ TILs from lung cancer patients also revealed high levels of PDCD1 (PD1) and HAVCR2 (TIM3), and low levels of the tissue egress marker S1PR1 (92).”
BackgroundInfluentialMurray, T., Fuertes Marraco, S. A., Baumgaertner, P., Bordry, N., Cagnon, L., Donda, A., Romero, P., Verdeil, G., & Speiser, D. E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00573 · Cited by 104
“Three recent reports have demonstrated that the presence of CD8+CD103+ TIL is associated with more favorable prognosis in ovarian (46), lung (21), and bladder cancer (22), but the importance of TRM cells for antitumor immunity remains to be determined.”
BackgroundResultTosi, A., Parisatto, B., Menegaldo, A., Spinato, G., Guido, M., Del Mistro, A., Bussani, R., Zanconati, F., Tofanelli, M., Tirelli, G., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02481-4 · Cited by 104
Yazdi, M. T., van Riet, S., van Schadewijk, A. M., Fiocco, M. F., van Hall, T., Taube, C., Hiemstra, P. S., & van der Burg, S. H. (2015) · Oncotarget · doi:10.18632/oncotarget.6506 · Cited by 105
Metabolic Reprogramming and Longevity of Tissue-Resident Memory T Cells
Pan, Y., & Kupper, T. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01347 · Cited by 106
Inhibitory checkpoint receptors control CD8+ resident memory T cells to prevent skin allergy
Gamradt, P., Laoubi, L., Nosbaum, A., Mutez, V., Lenief, V., Grande, S., Redoulès, D., Schmitt, A.-M., Nicolas, J.-F., & Vocanson, M. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.11.048 · Cited by 99
Resident memory T cells and cancer
Gavil, N. V., Cheng, K., & Masopust, D. (2024) · Immunity · doi:10.1016/j.immuni.2024.06.017 · Cited by 110
Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis
Soo, R. A., Chen, Z., Teng, R. S. Y., Tan, H.-L., Iacopetta, B. J., Tai, B. C., & Soong, R. (2018) · Oncotarget · doi:10.18632/oncotarget.24835 · Cited by 104
Burbach, B. J., O’Flanagan, S. D., Shao, Q., Young, K. M., Slaughter, J. R., Rollins, M. R., Street, T. J. L., Granger, V., Beura, L. K., Azarin, S. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24132-6 · Cited by 108
Tumor Resident Memory T Cells: New Players in Immune Surveillance and Therapy
Dumauthioz, N., Labiano, S., & Romero, P. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02076 · Cited by 102
“A correlation between a high CD103+ TIL density and patient survival was also shown in early stage NSCLC patients.”
InfluentialGaudreau, P.-O., Negrao, M. V., Mitchell, K. G., Reuben, A., Corsini, E. M., Li, J., Karpinets, T. V., Wang, Q., Diao, L., Wang, J., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.09.027 · Cited by 111
“CD8+ CD103+ TILs have previously been associated with increased overall survival in early stage NSCLC patients [33].”
BackgroundSteele, K. E., Tan, T. H., Korn, R., Dacosta, K., Brown, C., Kuziora, M., Zimmermann, J., Laffin, B., Widmaier, M., Rognoni, L., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0326-x · Cited by 97
IL-15 Overcomes Hepatocellular Carcinoma-Induced NK Cell Dysfunction
Easom, N. J. W., Stegmann, K. A., Swadling, L., Pallett, L. J., Burton, A. R., Odera, D., Schmidt, N. M., Huang, W., Fusai, G., Davidson, B. R., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01009 · Cited by 99
“A similar large clinical series would be required to assess whether the variable proportion of tissue-resident NK cells infiltrating liver tumors correlates with prognosis, as recently reported for lung-resident T cells (23, 24).”
BackgroundColton, M., Cheadle, E. J., Honeychurch, J., & Illidge, T. (2020) · Radiation Oncology · doi:10.1186/s13014-020-01678-1 · Cited by 98
“improved overall survival in lung and ovarian tumours [53, 54].”
BackgroundZamora, A. E., Crawford, J. C., Allen, E. K., Guo, X.-Z. J., Bakke, J., Carter, R. A., Abdelsamed, H. A., Moustaki, A., Li, Y., Chang, T., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat8549 · Cited by 100
Karaki, S., Blanc, C., Tran, T., Galy–Fauroux, I., Mougel, A., Dransart, E., Anson, M., Tanchot, C., Paolini, L., Gruel, N., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001948 · Cited by 101
Self-citationAbd Hamid, M., Wang, R.-Z., Yao, X., Fan, P., Li, X., Chang, X.-M., Feng, Y., Jones, S., Maldonado-Perez, D., Waugh, C., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0885 · Cited by 86
Gálvez-Cancino, F., López, E., Menares, E., Díaz, X., Flores, C., Cáceres, P., Hidalgo, S., Chovar, O., Alcántara-Hernández, M., Borgna, V., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1442163 · Cited by 86
Resident-Memory T Cells in Tissue-Restricted Immune Responses: For Better or Worse?
Steinbach, K., Vincenti, I., & Merkler, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02827 · Cited by 98
Dóra, D., Rivard, C. J., Yu, H., Bunn, P. A., Suda, K., Ren, S., Pickard, S. L., László, V., Harkó, T., Megyesfalvi, Z., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12741 · Cited by 97
Tieu, R., Zeng, Q., Zhao, D., Zhang, G., Feizi, N., Manandhar, P., Williams, A. L., Popp, B. A., Wood, M. A., Demetris, A. J., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add8454 · Cited by 92
Bone Marrow T Cells and the Integrated Functions of Recirculating and Tissue-Resident Memory T Cells
Di Rosa, F., & Gebhardt, T. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00051 · Cited by 84
Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity
Terry, S., Zaarour, R. F., Venkatesh, G. H., Francis, A., El‐Sayed, W., Buart, S., Bravo, P. E., Thiery, J., & Chouaïb, S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103044 · Cited by 96
“Thus, the acquisition of a more mesenchymal phenotype by cancer cells has been associated with deficiencies in the MHC I antigen presentation pathway [44–47], downregulation of E-Cadherin [37], which could be critical for the recognition of cancer cells by tumor infiltrating lymphocytes (TILs) expressing [48,49], hype…”
BackgroundTissue-resident immune cells: from defining characteristics to roles in diseases
Li, J., Chu, X., Li, C., & He, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02050-5 · Cited by 99
Fehlings, M., Jhunjhunwala, S., Kowanetz, M., O’Gorman, W. E., Hegde, P. S., Sumatoh, H., Lee, B. H., Nardin, A., Becht, É., Flynn, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0695-9 · Cited by 89
Hypoxia and antitumor CD8+ T cells: An incompatible alliance?
Vuillefroy de Silly, R., Dietrich, P.-Y., & Walker, P. R. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1232236 · Cited by 81
Seo, W., Shimizu, K., Kojo, S., Okeke, A., Kohwi-shigematsu, T., Fujii, S., & Taniuchi, I. (2020) · Nature Communications · doi:10.1038/s41467-020-15375-w · Cited by 95
FOXOs in cancer immunity: Knowns and unknowns
Deng, Y., Wang, F., Hughes, T. L., & Yu, J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.005 · Cited by 90
Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non–Small Cell Lung Cancer
O’Brien, S., Klampatsa, A., Thompson, J. C., Martinez, M. C., Hwang, W., Rao, A. S., Standalick, J. E., Kim, S., Cantu, E., Litzky, L. A., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0713 · Cited by 91
“Their presence has been reported as a positive prognostic factor for survival in lung cancer (7, 20) and other tumors (8, 9).”
BackgroundTissue patrol by resident memory CD8+ T cells in human skin
Dijkgraaf, F. E., Matos, T. R., Hoogenboezem, M., Toebes, M., Vredevoogd, D. W., Mertz, M., van den Broek, B., Song, J., Teunissen, M. B. M., Luiten, R. M., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0404-3 · Cited by 85
Weeden, C. E., Gayevskiy, V., Marceaux, C., Batey, D., Tan, T., Yokote, K., Ribera, N. T., Clatch, A., Christo, S. N., Teh, C. E., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.03.019 · Cited by 85
AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
Terry, S., Abdou, A., Engelsen, A. S. T., Buart, S., Dessen, P., Corgnac, S., Collares, D., Meurice, G., Gausdal, G., Baud, V., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0903 · Cited by 84
“Data were processed and analyzed as previously described (27).”
MethodSelf-citationImmunology of Adenoviral Vectors in Cancer Therapy
Shaw, A. R., & Suzuki, M. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.001 · Cited by 90
Zhang, C., Yin, K., Liu, S. M., Yan, L., Su, J., Wu, Y.-L. L. C., Zhang, X., Zhong, W., & Yang, X.-N. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002312 · Cited by 88
Targeting latency-associated peptide promotes antitumor immunity
Gabriely, G., da Cunha, A. P., Rezende, R. M., Kenyon, B., Madi, A., Vandeventer, T., Skillin, N., Rubino, S., Garo, L., Mazzola, M. A., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aaj1738 · Cited by 78
Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy
Gu, Y., Zhang, Z., & ten Dijke, P. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-00980-8 · Cited by 79
“This TIL subset displays increased cytolytic activity upon PD-1/PD-L1 blockade [219, 223], indicating that ICB therapy may be more effective in tumors with high E-cadherin expression.”
BackgroundKoh, J., Kim, S., Kim, M.-Y., Go, H., Jeon, Y. K., & Chung, D. H. (2017) · Oncotarget · doi:10.18632/oncotarget.14632 · Cited by 77
“Several recent lines of evidence suggest that CD8+CD103+ TILs account for the majority of CD103+ TILs [18, 20, 23].”
BackgroundResultInfluentialThe Whole Body as the System in Systems Immunology
Poon, M. M. L., & Farber, D. L. (2020) · iScience · doi:10.1016/j.isci.2020.101509 · Cited by 72
“…been shown to be enriched in tumor tissue, particularly in cancers of epithelial origin, and often correlate with improved patient survival (Boddupalli et al., 2016; Djenidi et al., 2015; Edwards et al., 2018; Komdeur et al., 2017; Smazynski and Webb, 2018; Wang et al., 2016; Webb et al., 2015).”
BackgroundMalenica, I., Adam, J., Corgnac, S., Mezquita, L., Auclin, É., Damei, I., Grynszpan, L., Gros, G., de Montpréville, V., Planchard, D., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25322-y · Cited by 84
Self-citationTargeting Resident Memory T Cells for Cancer Immunotherapy
Blanc, C., Hans, S., Tran, T., Granier, C., Saldman, A., Anson, M., Oudard, S., & Tartour, E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01722 · Cited by 68
“For example, TRM derived from NSCLC and melanoma did not express membrane CTLA-4 (19, 35), and in ovarian cancer, PD-1+CD103+CD8+ T cells exhibited a weak expression of other exhaustion-associated markers, such as CTLA-4, LAG-3, and TIM-3 (32).”
InfluentialCaetano, M. S., Younes, A. I. A., Barsoumian, H. B., Quigley, M. M., Menon, H., Gao, C., Spires, T. E., Reilly, T. P., Cadena, A. P., Cushman, T. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0795 · Cited by 77
“These cells are a tumor-specific cytotoxic T lymphocyte subpopulation that accumulates in the tumor microenvironment (28, 29) and express CD103 [aE (CD103) b7] and CD49a [a1 (CD49a) b1] integrins along with the C-type lectin CD69, which collectively help these cells to migrate into tumor islets by binding to E-cadheri…”
BackgroundKverneland, A. H., Chamberlain, C. A., Borch, T. H., Nielsen, M., Mørk, S. K., Kjeldsen, J. W., Lorentzen, C. L., Jørgensen, L. P., Riis, L. B., Yde, C. W., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003499 · Cited by 77
Tertiary lymphoid structures show infiltration of effective tumor‐resident T cells in gastric cancer
Mori, T., Tanaka, H., Suzuki, S., Deguchi, S., Yamakoshi, Y., Yoshii, M., Miki, Y., Tamura, T., Toyokawa, T., Lee, S., et al. (2021) · Cancer Science · doi:10.1111/cas.14888 · Cited by 75
Human mucosal tissue-resident memory T cells in health and disease
Lange, J., Rivera‐Ballesteros, O., & Buggert, M. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00467-7 · Cited by 77
Komdeur, F. L., Wouters, M. C. A., Workel, H. H., Tijans, A. M., Terwindt, A. L. J., Brunekreeft, K. L., Plat, A., Klip, H. G., Eggink, F. A., Leffers, N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12077 · Cited by 69
“In NSCLC, CD103+ TIL were found to be of a homogeneous CD69+ CD62L− CD28− CD27+ CD45RA+ CD45RO+ CCR7− subtype [16].”
Enhancing the efficacy of immunotherapy using radiotherapy
Keam, S., Gill, S., Ebert, M. A., Nowak, A. K., & Cook, A. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1169 · Cited by 69
“Interestingly, ex vivo PD-1 blockade on TRM isolated from patients with lung carcinomas greatly promoted lytic activity against tumor cells.(107) However, ICPB treatment may also be associated with TRM-related hyperinflammation.”
BackgroundIntegration of multiple “OMIC” biomarkers: A precision medicine strategy for lung cancer
Robles, A. I., & Harris, C. C. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.06.003 · Cited by 70
Tumor-resident memory T cells as a biomarker of the response to cancer immunotherapy
Damei, I., Trickovic, T., Mami‐Chouaib, F., & Corgnac, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1205984 · Cited by 70
“Cytotoxic activity toward malignant cells is mediated by the TCR and dependent on CD103 expression, as anti-CD103 neutralizing antibodies block CD103-Ecadherin interaction and inhibit target cell lysis (16, 17, 43).”
BackgroundInfluentialSelf-citationMeng, X., Gao, Y., Yang, L., Jing, H., Teng, F., Huang, Z., & Xing, L. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.09.012 · Cited by 66
Cho, J.-W., Park, S., Kim, G., Han, H., Shim, H. S., Shin, S., Bae, Y., Park, S. Y., Ha, S., Lee, I., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26362-0 · Cited by 75
Rausch, L., & Kallies, A. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-082223-044122 · Cited by 70
Ruiz-Ceja, K. A., & Chirino, Y. I. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.03.018 · Cited by 67
Joint together: The etiology and pathogenesis of ankylosing spondylitis
Xiong, Y., Cai, M., Xu, Y., Dong, P., Chen, H., He, W., & Zhang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.996103 · Cited by 72
Strategies for developing and optimizing cancer vaccines
Maeng, H. M., & Berzofsky, J. A. (2019) · F1000Research · doi:10.12688/f1000research.18693.1 · Cited by 68
Prognostic Factors and Biomarkers of Responses to Immune Checkpoint Inhibitors in Lung Cancer
Bianco, A., Perrotta, F., Barra, G., Malapelle, U., Rocco, D., & Palma, R. D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194931 · Cited by 68
“In that context as well, tumor infiltrating lymphocytes (TIL) (CD4+ and CD8+) are emerging as potential independent prognostic factors for overall survival (OS) and response rate (RR) regarding ICI treatment [9,10].”
BackgroundBoivin, G., Kalambaden, P., Faget, J., Rusakiewicz, S., Montay‐Gruel, P., Meylan, E., Bourhis, J., Lesec, G., & Vozenin, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00256 · Cited by 64
Cao, Q., Lu, J., Li, Q., Wang, C., Wang, X. M., Lee, V. W., Wang, C., Nguyen, H. P., Zheng, G., Zhao, Y., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015030229 · Cited by 64
Li, R., Liu, H., Cao, Y., Wang, J., Chen, Y., Qi, Y., Lv, K., Liu, X., Yu, K., Lin, C., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0813-y · Cited by 64
Hartana, C. A., Ahlén Bergman, E., Broomé, A., Berglund, S., Johansson, M., Alamdari, F., Jakubczyk, T., Huge, Y., Aljabery, F., Palmqvist, K., et al. (2018) · Clinical and Experimental Immunology · doi:10.1111/cei.13183 · Cited by 60
Chen, B., Li, H., Liu, C., Xiang, X., Wang, S., Wu, A., Shen, Y., & Li, G. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242173 · Cited by 104
MMP2 and TLRs modulate immune responses in the tumor microenvironment
Muniz-Bongers, L. R., McClain, C. B., Saxena, M., Bongers, G., Mérad, M., & Bhardwaj, N. (2021) · JCI Insight · doi:10.1172/jci.insight.144913 · Cited by 68
Jaiswal, A., Verma, A., Dannenfelser, R., Melssen, M. M., Tirosh, I., Izar, B., Kim, T., Nirschl, C. J., Devi, K. S. P., Olson, W. C., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.005 · Cited by 62
Heras‐Murillo, I., Mañanes, D., Munné, P., Núñez, V., Herrera, J., Català-Montoro, M., Álvarez, M., del Pozo, M. Á., Melero, I., Wculek, S. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58289-1 · Cited by 64
Paulsen, E., Kilvaer, T. K., Rakaee, M., Maurseth, R. J., Al‐Saad, S., Hald, S. M., Al-Shibli, K. I., Andersen, S., Richardsen, E. H., Busund, L., et al. (2015) · Neoplasia · doi:10.1016/j.neo.2015.11.004 · Cited by 64
“[34] found CD8CD103 TIL to be characteristic of tissue-resident memory T cells.”
BackgroundBiomarkers for immunotherapy for treatment of glioblastoma
Lynes, J. P., Nwankwo, A., Sur, H. P., Sanchez, V. E., Sarpong, K., Ariyo, O., Dominah, G. A., & Nduom, E. K.-E. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000348 · Cited by 63
TGF-β enhances the cytotoxic activity of Vδ2 T cells
Peters, C., Meyer, A., Kouakanou, L., Feder, J., Schricker, T., Lettau, M., Janßen, O., Wesch, D., & Kabelitz, D. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1522471 · Cited by 67
“Elevated numbers of CD103 TIL in non-small cell lung carcinoma as well as in ovarian cancer have been correlated with an increased survival.(39,40) Interestingly, the accumulation of CD103 T cells (including CD8 γδ T cells) has been reported for the fibrous stroma of PDAC.”
BackgroundThe Roles of Tissue-Resident Memory T Cells in Lung Diseases
Yuan, R., Yu, J., Jiao, Z., Li, J., Wu, F., Yan, R., Huang, X., & Chen, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710375 · Cited by 64
Gauthier, L., Corgnac, S., Boutet, M., Gros, G., Validire, P., Bismuth, G., & Mami‐Chouaib, F. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1487 · Cited by 61
Self-citationA new therapeutic target: the CD69-Myl9 system in immune responses
Kimura, M. Y., Koyama‐Nasu, R., Yagi, R., & Nakayama, T. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00734-7 · Cited by 64
PD-1 and TIM-3 differentially regulate subsets of mouse IL-17A–producing γδ T cells
Edwards, S. C., Hedley, A., Hoevenaar, W. H. M., Wiesheu, R., Glauner, T. A., Kilbey, A., Shaw, R., Boufea, K., Batada, N. N., Hatano, S., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20211431 · Cited by 59
“…1 phenotype (e.g. Amica1, Cxcr6, Icos, Pdcd1, and Tnfsf11) was highly reminiscent of CD8+ tissue resident memory (Trm) T cells (Clarke et al., 2019; Djenidi et al., 2015; Kumar et al., 2017; Mackay et al., 2013; Peng et al., 2022; Strutt et al., 2018;Wein et al., 2019), indicating that Cluster 1…”
Tassi, E., Grazia, G., Vegetti, C., Bersani, I., Bertolini, G., Molla, A., Baldassari, P., Andriani, F., Roz, L., Sozzi, G., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1387 · Cited by 58
de Groot, R., van Loenen, M. M., Guislain, A., Nicolet, B. P., Heeren, J. J. F., Verhagen, O. J. H. M., van den Heuvel, M. M., de Jong, J., Burger, P., van der Schoot, C. E., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1648170 · Cited by 61
Kalina, J. L., Neilson, D. S., Comber, A. P., Rauw, J. M., Alexander, A., Vergidis, J., & Lum, J. J. (2017) · Cancers · doi:10.3390/cancers9020013 · Cited by 58
Pu, X., Wu, L., Su, D., Mao, W., & Fang, B. (2018) · BMC Cancer · doi:10.1186/s12885-018-4990-5 · Cited by 58
Immune cellular components and signaling pathways in the tumor microenvironment
Yenyuwadee, S., Aliazis, K., Wang, Q., Christofides, A., Shah, R., Patsoukis, N., & Boussiotis, V. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.004 · Cited by 55
CD103 + T and Dendritic Cells Indicate a Favorable Prognosis in Oral Cancer
Xiao, Y., Li, H., Mao, L., Yang, Q. C., Fu, L., Wu, C. C., Liu, B., & Sun, Z. (2019) · Journal of Dental Research · doi:10.1177/0022034519882618 · Cited by 59
“Trms have also been investigated in many cancers, such as non–small cell lung carcinoma (NSCLC) (Djenidi et al. 2015) and ovarian cancer (Webb et al. 2014); these studies revealed that Trm subsets may be correlated with 1The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Labora…”
BackgroundInfluentialHamid, M. A., Colin‐York, H., Alham, N. K., Browne, M., Cerundolo, L., Chen, J., Yao, X., Rosendo-Machado, S., Waugh, C., Maldonado‐Pérez, D., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0554 · Cited by 55
“patients either with melanoma, colorectal, urothelial, or early stage lung cancers (3-7).”
BackgroundTuminello, S., Veluswamy, R. R., Lieberman‐Cribbin, W., Gnjatic, S., Petralia, F., Wang, P., Flores, R. M., & Taioli, E. (2019) · Oncotarget · doi:10.18632/oncotarget.27392 · Cited by 98
“Djenidi, 2015 [42] CD3 Total (tumor + stroma) OS & DFS Unadj n/a 101 68 I: 100 ADC: 45 Ever: 89% Continuous variables CD8 SCC: 42”
Natural Killer Cell Integrins and Their Functions in Tissue Residency
Shannon, M. J., & Mace, E. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.647358 · Cited by 56
“αE uses binding to E-cadherin to localize T cells to epithelial tissues in the lung (212).”
BackgroundWang, Z., Ahmed, S. U., Labib, M., Wang, H., Wu, L., Bavaghar-Zaeimi, F., Shokri, N., Blanco, S., Karim, S., Czarnecka‐Kujawa, K., et al. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01023-3 · Cited by 54
A Yin and Yang in Epithelial Immunology: The Roles of the αE(CD103)β7 Integrin in T Cells
Hardenberg, J.-H., Braun, A., & Schön, M. P. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.05.026 · Cited by 56
Tissue-Resident Lymphocytes Across Innate and Adaptive Lineages
Chou, C., & Li, M. O. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02104 · Cited by 58
Blockade of TGF-β signaling: a potential target for cancer immunotherapy?
Ungefroren, H. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1636034 · Cited by 50
Expanding the Spectrum of Adenoviral Vectors for Cancer Therapy
Gao, J. J., Zhang, W., & Ehrhardt, A. (2020) · Cancers · doi:10.3390/cancers12051139 · Cited by 54
Tissue-resident memory CD8+ T cells in cancer immunology and immunotherapy
Wang, T., Shen, Y., Luyten, S., Yang, Y., & Jiang, X. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104876 · Cited by 55
Hu, X., Li, Y.-Q., Li, Q.-G., Ma, Y.-L., Peng, J.-J., & Cai, S. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.003 · Cited by 58
Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma
Withers, S. S., Skorupski, K. A., York, D. S., Choi, J. W., Woolard, K., Amorim, R. L., Sparger, E. E., Rodriguez, C. O., McSorley, S. J., Monjazeb, A. M., et al. (2018) · Veterinary and Comparative Oncology · doi:10.1111/vco.12444 · Cited by 57
Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes
Klampatsa, A., O’Brien, S., Thompson, J. C., Rao, A. S., Stadanlick, J. E., Martinez, M. C., Liousia, M., Cantu, E., Cengel, K. A., Moon, E. K., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1638211 · Cited by 54
“Trms are a subset of differentiated effector CD8+ T cells that permanently reside in mucosal tissues and can be characterized in the lung by expression of the integrin αeβ7 (CD103) and the surface T cell activation marker CD69.(12,13) Although Trms express high levels of multiple IRs, they also have high levels of “de…”
BackgroundChen, L., Sun, R., Xu, J., Zhai, W., Zhang, D., Yang, M., Yue, C., Chen, Y., Li, S., Turnquist, H. R., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-1024 · Cited by 57
“Ample studies have established that the number of resident CD8þ T cells in the tumor tissue correlates with better prognosis (7, 8).”
BackgroundMassi, D., Romano, E., Rulli, E., Merelli, B., Nassini, R., Logu, F. D., Bièche, I., Baroni, G., Cattaneo, L., Xue, G., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.03.012 · Cited by 53
“This represents a subgroup of tissue-resident memory T cells, which express the inhibitory checkpoints PD-1 and Tim3, indicating a preexisting antigen-specific immune activation associated with a T-cell-inflamed tumour environment [26].”
BackgroundGoing to extremes: determinants of extraordinary response and survival in patients with cancer
Saner, F. A. M., Herschtal, A., Nelson, B. H., deFazio, A., Goode, E. L., Ramus, S. J., Pandey, A., Beach, J. A., Fereday, S., Berchuck, A., et al. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0145-5 · Cited by 51
Tissue Site and the Cancer Immunity Cycle
Horton, B. L., Fessenden, T. B., & Spranger, S. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.07.006 · Cited by 59
“In contrast to Treg, tissue-resident memory CD8+ T cells are thought to be beneficial to anti-tumor immunity, and their presence correlates with a better prognosis in lung cancer patients [21, 22].”
BackgroundCancer-specific tissue-resident memory T-cells express ZNF683 in colorectal cancer
Kitakaze, M., Uemura, M., Hara, T., Chijimatsu, R., Motooka, D., Hirai, T., Konno, M., Okuzaki, D., Sekido, Y., Hata, T., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02202-4 · Cited by 49
Human T lymphocytes at tumor sites
Notarbartolo, S., & Abrignani, S. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00970-4 · Cited by 55
“The expression of immune checkpoint receptors by tumor-infiltrating human CD8+ TRM cells has been confirmed at the protein level by several independent studies [17, 103, 105, 113, 117, 164].”
BackgroundResult
Metadata
- Authors
- Djenidi, F., Adam, J., Goubar, A., Durgeau, A., Meurice, G., de Montpréville, V., Validire, P., Besse, B., & Mami-Chouaib, F.
- Affiliations
- Université Paris-Sud (FR)
- INSERM Unité 1186 , 94805 Villejuif ,
- Institute Mutualiste Montsouris (FR)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-01
- Volume
- 194
- Issue
- 7
- Pages
- 3475-3486
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1895620535
- Cited by
- 622
- References
- 51
- Citations by year
- 2026: 34 · 2025: 61 · 2024: 51 · 2023: 55 · 2022: 63 · 2021: 81 · 2020: 72 · 2019: 70 · 2018: 66 · 2017: 27 · 2016: 28 · 2015: 13
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut Gustave-Roussy
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-infiltrating lymphocytes, tissue-resident memory T cells, non-small cell lung cancer, PD-1, TIM-3, immune checkpoint blockade, T cell exhaustion, intraepithelial lymphocytes, patient survival, prognostic factors, T cell cytotoxicity
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Cytotoxicity, Immunologic, Female, Humans, Immunologic Memory, Lung Neoplasms, Lymphocyte Activation, Male, Membrane Proteins, Middle Aged, Neoplasm Staging, Organ Specificity, Prognosis, Risk Factors, Antigens, CD, Immunophenotyping, Lymphocytes, Tumor-Infiltrating, CD8 Antigens, Gene Expression Profiling, Integrin alpha Chains, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.